We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cello Health Plc | LSE:CLL | London | Ordinary Share | GB00B0310763 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 161.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLL
RNS Number : 5783P
Cello Health PLC
29 May 2018
29 May 2018
Cello Health plc
("Cello" or "the Company")
Director / PDMR Dealings and Total Voting Rights
The Company notifies that, on 25 May 2018, Richard Marsham and Minh Huynh, both of whom are persons discharging managerial responsibilities of the Company, exercised options over 46,000, and 15,321 ordinary shares of 10 pence each ("Shares") in the capital of the Company respectively. The new Shares will rank pari-passu with existing Shares and have been admitted to trading under the Company's existing block listing. The exercise prices paid were as follows:
Name Number of Exercise price Type of option options exercised paid per share scheme (p) ----------------- ------------------- ---------------- ---------------- Approved Share Richard Marsham 17,428 42 Option Plan ----------------- ------------------- ---------------- ---------------- PSP Option Richard Marsham 16,000 10 Scheme ----------------- ------------------- ---------------- ---------------- Unapproved Richard Marsham 12,572 42 Option Plan ----------------- ------------------- ---------------- ---------------- Approved Option Minh Huynh 15,321 50 Plan ----------------- ------------------- ---------------- ----------------
Following the above exercise of options, Richard Marsham and Minh Huynh sold 46,000 and 15,321 Shares respectively, all at a price of 122 pence per share.
Following the issue of the new Shares, Cello's issued share capital will comprise 105,112,253 Ordinary Shares, of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company is therefore 104,659,253 Ordinary Shares.
The above figure of 104,659,253 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Cello Health plc 020 7812 8460 Mark Scott, Chief Executive Mark Bentley, Finance Director Cenkos Securities plc 0207 397 8900 Mark Connelly Harry Hargreaves
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated ---- -------------------------------------------------------------------------- a) Name Richard Marsham ---- -------------------------- ---------------------------------------------- 2 Reason for the notification ---- -------------------------------------------------------------------------- a) Position/status PDMR and director of Cello Signal ---- -------------------------- ---------------------------------------------- b) Initial notification Initial notification /Amendment ---- -------------------------- ---------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- -------------------------------------------------------------------------- a) Name Cello Health plc ---- -------------------------- ---------------------------------------------- b) LEI 2138004TZYGZLWQP7N64 ---- -------------------------- ---------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- -------------------------------------------------------------------------- a) Description of Options over ordinary shares the financial of 10 pence each instrument, type of instrument ---- Identification ISIN: GB00B0310763 code ---- -------------------------- ---------------------------------------------- b) Nature of the 1. Exercise of options over transaction Ordinary Shares of 10 pence each, pursuant to Approved Share Option Plan 2. Exercise of options over Ordinary Shares of 10 pence each, pursuant to PSP Option Scheme 3. Exercise of options over Ordinary Shares of 10 pence each, pursuant to Unapproved Option Plan 4. Sale of Ordinary Shares ---- -------------------------- ---------------------------------------------- c) Price(s) and volume(s) ---- ------------------ ---------------- Price(s) Volume(s) ---- ------------------ ---------------- 1. 42p per 1. 17,428 share 2. 10p per 2. 16,000 share 3. 42p per 3. 12,572 share 4. 122p per 4. 42,000 share ------------------ ---------------- d) Aggregated information ---- - Aggregated volume 46,000 - Price Weighted average exercise price of 30.87p per share e) Date of the transaction 25 May 2018 ---- -------------------------- ---------------------------------------------- f) Place of the transaction 1,2,3 - Outside trading venue 4. London Stock Exchange ---- -------------------------- ---------------------------------------------- 1 Details of the person discharging managerial responsibilities / person closely associated --- ------------------------------------------------------------------------------- a) Name Minh Huynh --- ------------------------- ---------------------------------------------------- 2 Reason for the notification --- ------------------------------------------------------------------------------- a) Position/status PDMR and director of Cello Signal --- ------------------------- ---------------------------------------------------- b) Initial notification Initial notification /Amendment --- ------------------------- ---------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ------------------------------------------------------------------------------- a) Name Cello Health plc --- ------------------------- ---------------------------------------------------- b) LEI 2138004TZYGZLWQP7N64 --- ------------------------- ---------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------------------------------- a) Description of Options over ordinary shares the financial of 10 pence each instrument, type of instrument --- Identification ISIN: GB00B0310763 code --- ------------------------- ---------------------------------------------------- b) Nature of the 1. Exercise of options over transaction Ordinary Shares of 10 pence each, pursuant to Approved Share Option Plan 2. Sale of Ordinary Shares --- ------------------------- ---------------------------------------------------- c) Price(s) and volume(s) --- ------------------ ---------------------- Price(s) Volume(s) --- ------------------ ---------------------- 1. 50p per 1. 15,321 share 2. 122p per 2. 15,321 share ------------------ ----------------------
d) Aggregated information N/A - single transaction --- - Aggregated volume - Price e) Date of the transaction 25 May 2018 --- ------------------------- ---------------------------------------------------- f) Place of the transaction 1. Outside trading venue 2. London Stock Exchange --- ------------------------- ----------------------------------------------------
About Cello Health plc
We are a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York, Philadelphia, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHFKCDQQBKDQPB
(END) Dow Jones Newswires
May 29, 2018 10:45 ET (14:45 GMT)
1 Year Cello Health Chart |
1 Month Cello Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions